Elekta Announces Mid‑Term Targets Ahead of Capital Markets Day

Swedish medical‑technology firm Elekta disclosed new mid‑term financial targets on 17 June 2026, ahead of its Capital Markets Day in Stockholm. The announcement triggered a share price decline of more than 3 % on the same trading day.

Elekta outlined a strategic plan built around four “Must‑Win Battles,” which include a new operating model to accelerate innovation velocity and execution speed, a more focused gross R&D spend, and clearer regional strategies for its key markets—specifically the United States, China and Europe.

Mid‑Term Targets (FY 2025/26 to FY 2028/29)

  • Sales growth: The company targets a mid‑single‑digit compound annual growth rate (CAGR) in constant currency over the period.
  • Adjusted EBIT margin: A range of 14 % to 16 % is set for FY 2028/29.
  • Free cash flow before dividend: Targeted at approximately 10 % of sales in FY 2028/29.

These longer‑term objectives are expected to be driven by expansion across all regions, with the United States, China and Europe identified as the primary growth engines. Margin improvement is anticipated from a better product mix—particularly increased adoption of adaptive radiotherapy—price enhancements across the portfolio, and productivity gains.

Near‑Term Outlook (FY 2026/27)

  • Sales growth: Expected 2 % to 4 % in constant‑currency terms.
  • Adjusted EBIT margin: Projected between 12.5 % and 13.5 %.

The FY 2026/27 guidance aligns with the figures previously released in Elekta’s Q4 2025/26 report.